An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2017 Status changed from not yet recruiting to recruiting.
- 29 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 3 Apr 2017.